I tend to agree with some of the sentiment here. For me, the sentences below show both confidence and frustration. My guess is that Mr market is waiting for the company to kick one or two more goals before this re-rates. The company has been saying for some time now that big pharma is definitely interested. Perhaps things are finally coming to a head and this is a way of giving the market a heads up...
"PXS have one of the only unencumbered clinical stage assets in the anti‐fibrotic space. It is an obvious acquisition target for consolidators looking for combination therapies".
"The range of upfronts/acquisition prices paid (before earn outs) for Pre‐clinical to PhII assets in the last 2 years has been ~$50‐400m. Pharmaxis’ current EV is ~$60m. If the market won’t value the asset appropriately big pharma will."
Ann: Investor Briefing - Presentation, page-10
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.002(4.76%) |
Mkt cap ! $54.92M | |||
| Open | High | Low | Value | Volume |
| 4.2¢ | 4.2¢ | 4.0¢ | $89.87K | 2.189M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 312221 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 500000 | 1 |
View Market Depth
| Last trade - 12.13pm 09/10/2024 (20 minute delay) ? |
| SNT (ASX) Chart |